Yinming biological HPK1 small molecule inhibitor new drug has passed the United States ind, and the dry amd small molecule new drug has completed the phase I clinical trial in the United States

Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis

‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’

Cellatopia Secures Nearly CNY Ten Mn in Seed Funding

EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).

Haier Biomedical 'Smart Blood City Network' Lands in Brazil

Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.

D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline

EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.

EqualOcean | Southern Weekly 2022 'China Greenwashing List'

Nine companies have been listed on China's Greenwashing List, drawing wider attention to the issue of greenwashing.